Viral Systems Biology Center focusing on Ebola, Lassa, and COVID-19
Center for Viral Systems Biology (CViSB)
This center works to find biological and environmental factors that predict who will get mild versus severe illness from Ebola, Lassa fever, or COVID-19 to help guide care and prevention.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11289299 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers will combine clinical records, blood and other samples, genetic tests, and virus sequencing from people affected by Ebola, Lassa, and COVID-19. They will use computer-based systems biology to look for patterns linking immune responses, genetics, and virus features with outcomes. The center links labs and clinics, including partners in areas where these infections are common, and uses a reverse-translational approach to turn lab findings into practical markers. The goal is to discover reliable signals that could be used to predict disease severity and inform treatments or public-health actions.
Who could benefit from this research
Good fit: Ideal candidates are people who have or recently had Ebola, Lassa fever, or COVID-19 and who receive care at participating hospitals or partner sites, including clinics in endemic regions.
Not a fit: People without these infections or those needing immediate lifesaving treatment are unlikely to receive direct benefits from this research right away.
Why it matters
Potential benefit: If successful, this work could produce tests or markers that help doctors predict who is at higher risk of severe illness and tailor care or prevention steps.
How similar studies have performed: Previous systems-biology studies have identified immune and genetic markers for severe outcomes in COVID-19 and other infections, but this center expands that work across multiple high-priority viruses and moves toward clinical application.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Andersen, Kristian Graugaard — Scripps Research Institute, the
- Study coordinator: Andersen, Kristian Graugaard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.